The present application relates to methods of preventing, treating or managing a respiratory disease and/or a viral infection (e.g., an influenza virus infection and COVID-19) using a pharmaceutical composition produced from one or more preparations of plant parts. Provided herein are the pharmaceutical compositions produced from the one or more preparations. Also provided herein are methods of producing the pharmaceutical composition from the one or more preparations.

The present application relates to methods of preventing, treating or managing chronic obstructive pulmonary disease (COPD) and/or other obstructive lung diseases using a pharmaceutical composition produced from one or more preparations of plant parts. Provided herein are the pharmaceutical compositions produced from the preparations. Also provided herein are methods of producing the pharmaceutical compositions.

Disclosed herein are embodiments of cannabis extraction methods, apparatuses for extracting cannabis, and methods of using cannabis extracts.

The present invention relates to the field of herbal compositions. In particular, the present invention is directed to an Improved Herbal Extract Composition comprising a Melissa species extract, an Avena species extract, a Tilia species extract and a unique blend of citrus components. The composition can further comprise at least one additional extract of a plant such as Citrus species, Crataegus species, Panax species, and Lavendula species. The herbal extract composition is useful in numerous ingestible forms including an extract concentrate for food and beverage preparation, additive or enhancer for existing foods and beverages and particularly in the form of a pleasant tasting and soothing beverage.

A method of treating hypertension can include administering to a patient in need thereof a therapeutically effective amount of an extract of Matricaria chamomilla L. The extract can be administered orally to the patient in an amount of about 100 mg/kg to about 200 mg/kg.

Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

The invention relates to a method for obtaining a composition based on conifer bark enriched in dihydroquercetin or in tannins, comprising the following steps: a) grinding dried shavings of bark from a conifer to obtain a ground particulate material of conifer bark, and b) selecting, from the ground particulate material obtained in step a), the fraction of particles: of smallest size representing at most 40% by weight, relative to the total weight of the ground particulate material obtained in step a), this fraction being enriched in tannins; or of largest size representing at most 50% by weight, relative to the total weight of the ground particulate material obtained in step a), this fraction being enriched in dihydroquercetin.

The cis-isomer and trans-isomers of the plant-derived compound gnetin H are shown have anticancer properties, anti-inflammatory properties, and low toxicity. Therapeutic and prophylactic compositions that contain cis-gnetin H, trans-gnetin H, an derivatives thereof, as well as methods of making and using said compositions, are provided, cis-gnetin H and/or trans-gnetin H can be used in purified form or as a plant extract.

The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

The present disclosure relates to polygalacturonan rhamnogalacturonan (PGRG1) compositions, as well as methods of making and methods of using said compositions in medicinally useful and pharmaceutically useful forms. Specifically, the present disclosure provides purified PGRG1 compositions isolated from roots of the Astragalus genus of plants, and more particularly from the species Astragalus membranaceus, as well as PGRG1 compositions having a weight average molecular weight of at least 40 kiloDaltons (kDa).